IsoRay (ISR) Reports Q3 Loss of $0.02/Share

Go back to IsoRay (ISR) Reports Q3 Loss of $0.02/Share

IsoRay, Inc. Reports Third Quarter Results

May 18, 2015 8:30 AM EDT

RICHLAND, WA -- (Marketwired) -- 05/18/15 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, announced its financial results for the quarter and nine months ended March 31, 2015. Recent publications are having a positive impact in the marketplace with new institutions seeking licenses to offer Cesium-131 treatment. While revenue increased a nominal two percent between the quarter ended March 31, 2014 and the quarter ended March 31, 2015, revenue was basically flat when comparing the nine... More